NAFLD Linked to Smaller Total Cerebral Brain Volume

Share this content:
NAFLD Linked to Smaller Total Cerebral Brain Volume
NAFLD Linked to Smaller Total Cerebral Brain Volume

MONDAY, Nov. 20, 2017 (HealthDay News) -- Nonalcoholic fatty liver disease (NAFLD) is associated with smaller total cerebral brain volume, according to a study published online Nov. 20 in JAMA Neurology.

Galit Weinstein, Ph.D., from the University of Haifa in Israel, and colleagues examined the correlation between prevalent NAFLD and brain magnetic resonance imaging measures in a cross-sectional study involving 766 individuals from the Offspring cohort of the Framingham Study. Participants were eligible if they did not have excessive alcohol intake and were free of stroke and dementia.

The researchers found that even after adjustment for all covariates, including age, sex, alcohol consumption, visceral adipose tissue, body mass index, menopausal status, systolic blood pressure, hypertension, current smoking, cardiovascular disease, physical activity, and insulin resistance, there was a significant correlation for NAFLD with smaller total cerebral brain volume. The differences in total cerebral brain volume for those with and without NAFLD corresponded to 4.2 and 7.3 years of brain aging in the general sample and in individuals aged younger than 60 years, respectively. There were no significant correlations seen between NAFLD and hippocampal or white matter hyperintensity volumes or covert brain infarcts.

"Nonalcoholic fatty liver disease is associated with a smaller total cerebral brain volume, independent of visceral adipose tissue and cardiometabolic risk factors, pointing to a possible link between hepatic steatosis and brain aging," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »